Cleale R M, Hart K B, Hutchens D E, Johnson E G, Paul A J, Smith L L, Tucker C, Yazwinski T A, Doscher M E, Grubbs S T, Wulster-Radcliffe M, Amodie D M
Fort Dodge Animal Health, P.O. Box 5366, Princeton, NJ 08543, USA.
Vet Parasitol. 2004 Dec 15;126(3):325-38. doi: 10.1016/j.vetpar.2004.08.010.
Trials were conducted in Arkansas, Idaho, Illinois and Wisconsin using a common protocol to evaluate effectiveness and safety of a long acting (LA), oil-based injectable formulation of moxidectin in beef cattle grazing spring and/or summer pastures. At each site, 150 cattle (steers and/or heifers) were blocked based on pretreatment fecal strongyle egg counts (EPG) and then randomly assigned to treatments within blocks. Presence of naturally acquired parasitic infections, confirmed by presence of parasite eggs in feces, was a prerequisite for study enrollment. Within each block of three animals, two received moxidectin LA injectable on day 0 at a dosing rate of 1.0 mg moxidectin/kg b.w. into the dorsal aspect of the proximal third of the ear, and one received a placebo control treatment. Cattle were weighed before treatment and on day 55 or 56 (55/56) after treatment. Fecal samples were also collected from 10 randomly selected blocks of animals at each site on days 14, 28 and 55/56 for EPG quantification. Average daily gain (ADG) was computed over the posttreatment period. Data pertaining to ADG and EPG were combined across sites and analyzed by mixed model analysis of variance to assess the fixed effect of treatment and random effects of site, block within site and the treatment by site interaction. Compared to placebo-treated controls, the geometric means of fecal EPG counts from cattle treated with moxidectin LA injectable were reduced 99.8% 14 days after treatment, 99.1% 28 days after treatment and 96.7% 55/56 days after treatment. Rate of weight gain by cattle treated with moxidectin LA injectable was 0.59 kg/day, or 23% (0.11 kg/day) more than placebo-treated controls (P<0.05). None of the cattle treated with moxidectin LA injectable exhibited signs of macrocyclic lactone toxicosis. Summarized across all study sites, proportions of cattle that received concurrent therapeutic treatments were similar among treatment groups. Study results demonstrate that moxidectin cattle LA injectable administered at a dosing rate of 1.0 mg moxidectin/kg b.w. to grazing beef cattle was effective and safe.
在美国阿肯色州、爱达荷州、伊利诺伊州和威斯康星州开展了试验,采用通用方案评估莫昔克丁长效油基注射剂对春季和/或夏季牧场放牧肉牛的有效性和安全性。在每个试验地点,根据治疗前粪便中圆线虫卵计数(EPG)将150头牛(公牛和/或小母牛)进行分组,然后在组内随机分配处理。粪便中存在寄生虫卵,证实存在自然感染的寄生虫,是纳入研究的前提条件。在每组三头牛中,两头在第0天接受剂量为1.0毫克莫昔克丁/千克体重的莫昔克丁长效注射剂,注射于耳近端三分之一的背侧,一头接受安慰剂对照处理。在处理前和处理后第55或56天对牛进行称重。在第14、28和55/56天,还从每个试验地点随机选择的10组动物中采集粪便样本,用于EPG定量。在处理后期间计算平均日增重(ADG)。将各试验地点有关ADG和EPG的数据合并,并通过混合模型方差分析进行分析,以评估处理的固定效应以及试验地点、试验地点内组和处理与试验地点交互作用的随机效应。与接受安慰剂处理的对照组相比,接受莫昔克丁长效注射剂处理的牛粪便EPG计数的几何平均数在处理后14天降低了99.8%,在处理后28天降低了99.1%,在处理后55/56天降低了96.7%。接受莫昔克丁长效注射剂处理的牛的增重率为0.59千克/天,比接受安慰剂处理的对照组高23%(0.11千克/天)(P<0.05)。接受莫昔克丁长效注射剂处理的牛均未表现出大环内酯类中毒迹象。汇总所有研究地点的数据,各处理组中接受同期治疗的牛的比例相似。研究结果表明,以1.0毫克莫昔克丁/千克体重的剂量给放牧肉牛注射莫昔克丁长效注射剂是有效且安全